Plasma is a component of blood that is acquired through blood fractionation, and plasma fractionation is the process of separating different components of plasma. Plasma can be isolated and used in a variety of medical procedures. When whole blood is donated, plasma can also be obtained from the donor. Plasmapheresis is a procedure that keeps the plasma after separating it from the blood cells. To replenish clotting factors, this plasma can be used as Fresh Frozen Plasma (FFP). The majority of goods made by plasma fractionation use plasma. Only roughly 20 of the thousands of different proteins found in plasma are employed to create therapeutic plasma products. They fall under the categories of albumin, clotting factors, and immunoglobulins.
This market’s expansion is mostly attributable to rising rates of immunological and bleeding disorders, an ageing population, and rising immunoglobulin and alpha-1-antitrypsin usage. In addition to being utilised as a packaging material for industrial applications, plasma fractionation is used to address protein deficit in healthcare settings. Plasma fractionation’s main purpose is to remove or inactivate viruses and prions.
To Get More Business Strategies Request for Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/529
Note – Updated Version 2023 is available
🠺 Brief Introduction to the research report.
🠺 Table of Contents (Scope covered as a part of the study)
🠺 Top players in the market
🠺 Research framework (structure of the report)
🠺 Research methodology adopted by Coherent Market Insights
The Centers for Disease Control (CDC) reports that in 2012, chronic diseases accounted for one of the leading causes of mortality and disability in the United States, affecting an estimated 117 million individuals. An increase in the incidence and prevalence of chronic diseases around the world, as well as the comfort of access to healthcare, are some of the factors contributing to the rising demand for plasma-derived products and are anticipated to propel the plasma fractionation market over the course of the forecast period. In part because the likelihood of haemophilia consequences, such as cerebral bleeding, inhibitor development, and joint problems, increases with age, the world’s ageing population is a significant factor in the plasma fractionation market.
The Centers for Disease Control and Prevention (CDC) estimate that every year in the United States, 400 babies are hemophilic. Although it is relatively uncommon, haemophilia is the most well-known inherited bleeding illness. Increasing plasma derivative costs, associated risk problems, and restrictive reimbursement rules may restrain the development of this sector. Over the forecast period, the worldwide plasma fractionation market is anticipated to be constrained by the rising use of recombinant proteins and products that serve as replacements for plasma products.
Due to rising per capita healthcare spending in the U.S., North America now dominates the global plasma fractionation industry. However, people’ aspirations for better and more sophisticated healthcare facilities are growing, as is their adoption of cutting-edge technologies. Due to factors like the rising prevalence of haemophilia in developing nations like China and India and the region’s ageing population, the Asia Pacific region is also expected to experience the highest CAGR during the projected period.
The primary market share of the plasma fractionation market was held by CSL Ltd., Octapharma AG, Grifols S.A, Baxalta Incorporated, Octapharma AG, and Kedrion S.p.A. These companies will continue to dominate the industry. Other significant players include Laboratoire Français du Fractionnement et des Biotechnologies, Bio Products Laboratory, Sanquin, China Biologic Products, Inc., and Biotest AG.
Direct Buy This Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/529
Plasma Fractionation Market Report Coverage
- In September 2019, a new plasma fractionation plant was opened in Bila Tserkva, Ukraine, by Biopharma, a firm with roots in Ukraine that specialises in the production of plasma-based, recombinant, and other pharmaceuticals. The company has GMP-certified equipment and facilities, and it offers a special plasma fractionation technology that enables the processing of the blood’s plasma components for the extraction of life-saving medications. With the company’s founding, Ukraine is now almost on par with the States, Austria, and Germany. The facility’s blood product manufacture, including Albumin, Bioven, and Immunoglobulin, is anticipated to aid in the treatment of illnesses brought on by immunodeficiency.
- In order to build laboratories for plasmapheresis, Egypt launched a project in June 2019 to set up a blood plasma fractionation and processing factory in the nation.
- At Technoparc, Montreal, Green Cross Biotherapeutics opened a new plasma fractionation facility in 2017. The project received a $21.4 million grant from the Quebec government.
- In order to create immunity against Ebola, the Probitas Foundation and Grifols, S.A. promoted plasma donations from Ebola survivors in 2017. Grifols S.A. established a plasmapheresis plant in order to handle plasma donations from the Ebola survivors.
Plasma Fractionation Market Taxonomy
By Product Type
- Coagulation Factor Concentrates
- Critical Care
By End User
- Clinical Research Laboratories
- North America
- Latin America
- Asia Pacific
- Middle East
We Offer Customized Report, Click Here @ https://www.coherentmarketinsights.com/insight/request-customization/529
Table of Content (TOC):
Chapter 1 Introduction and Overview
Chapter 2 Industry Cost Structure and Economic Impact
Chapter 3 Rising Trends and New Technologies with Major Key players
Chapter 4 Plasma Fractionation Market Analysis, Trends, Growth Factor
Chapter 5 Plasma Fractionation Market Application and Business with Potential Analysis
Chapter 6 Market Segment, Type, Application
Chapter 7 Plasma Fractionation Market Analysis (by Application, Type, End User)
Chapter 8 Major Key Vendors Analysis of Plasma Fractionation Market
Chapter 9 Development Trend of Analysis
Chapter 10 Conclusion
Explore More Reports
Middle east and turkey hemophilia treatment market
Rest of the world factor viii deficiency treatment market
Colombia wound care biologics market
India immune oncology drugs market
Halal nutraceuticals and vaccines market
Ambulatory surgical center market
Bipolar disorders treatment market
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame
CA 94010, United States
Phone: U.S.: +1-206-701-6702